Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222346 | 1.00 | PTGDR2 (0.41) | PTGDR2SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL2062805 | 1.00 | PTGDR2 (0.41) | PTGDR2SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL11467456 | 0.98 | PTGDR2 (0.43) | PTGDR2SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL1471858 | 0.87 | TSHR (0.36) | PTGDR2SLC6A3TSHR | |
| SCHEMBL25188997 | 0.85 | SLC6A2 (0.43) | PTGDR2SLC6A3SLC6A2SLC6A4TSHR | |
| SCHEMBL290175 | 0.84 | TSHR (0.45) | PTGDR2SLC6A3SLC6A2SLC6A4TSHR | |
| Bromide SCHEMBL17076644 | 0.82 | TSHR (0.35) | SLC6A3SLC6A2SLC6A4DHFRTSHR | |
| Bromide SCHEMBL17076627 | 0.82 | TSHR (0.35) | SLC6A3SLC6A2SLC6A4DHFRTSHR | |
| Bromide SCHEMBL17076628 | 0.82 | TSHR (0.35) | SLC6A3SLC6A2SLC6A4DHFRTSHR | |
| SCHEMBL28336946 | 0.81 | PTGDR2 (0.43) | PTGDR2SLC6A3SLC6A2SLC6A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-215554347-U | Simple and easy partial shipment device of cyclopentyl methyl mandelate | 天津佶品佳化工科技有限公司 | 2022-01-18 | — | — | CN | claimed |
| CN-215554347-U | Simple and easy partial shipment device of cyclopentyl methyl mandelate | 天津佶品佳化工科技有限公司 | 2022-01-18 | — | — | CN | disclosed |
| CN-215554347-U | Simple and easy partial shipment device of cyclopentyl methyl mandelate | 天津佶品佳化工科技有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-8628759-B2 | Soft anticholinergic esters | BODOR LABORATORIES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8568699-B2 | Soft anticholinergic zwitterions | BODOR LABORATORIES, INC. | 2013-10-29 | — | — | US | disclosed |
| US-20120177590-A1 | SOFT ANTICHOLINERGIC ESTERS | BODOR LABORATORIES, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120141401-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | BODOR LABORATORIES, INC. | 2012-06-07 | — | — | US | disclosed |
| US-8147809-B2 | Soft anticholinergic esters | BODOR LABORATORIES, INC. | 2012-04-03 | — | — | US | disclosed |
| US-8071639-B2 | Soft anticholinergic zwitterions | BODOR LABORATORIES, INC. | 2011-12-06 | — | — | US | disclosed |
| US-20090263341-A1 | SOFT ANTICHOLINERGIC ESTERS | BODOR LABORATORIES, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20080242651-A1 | 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-10-02 | — | — | US | disclosed |
| US-7417147-B2 | muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-08-26 | — | — | US | disclosed |
| EP-1957451-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | Bodor, Nicholas S. (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1948596-A2 | SOFT ANTICHOLINERGIC ESTERS | Bodor, Nicholas S. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-7399861-B2 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2008-07-15 | — | — | US | disclosed |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2007-05-31 | — | — | US | disclosed |
| WO-2007058971-A2 | SOFT ANTICHOLINERGIC ESTERS | BODOR NICHOLAS S (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059021-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | BODOR NICHOLAS S (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-0012071-A1 | Azoniaspiro derivatives, process for their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263341-A1 | SOFT ANTICHOLINERGIC ESTERS | CHRM2, CHRM1, CHRM3 | PTGDR2 553/4885SLC6A3 578/4885SLC6A2 528/4885 |
| US-20120177590-A1 | SOFT ANTICHOLINERGIC ESTERS | CHRM2, CHRM1, CHRM3 | PTGDR2 553/4885SLC6A3 578/4885SLC6A2 528/4885 |
| US-20120141401-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | CHRM2, CHRM1, CHRM3 | PTGDR2 772/4885SLC6A3 160/4885SLC6A2 229/4885 |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | CHRM2, ADRB2, ADRB1 | PTGDR2 147/4885SLC6A3 1441/4885SLC6A2 1494/4885 |
| US-20080242651-A1 | 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | CHRM2, CHRM1, CHRM3 | PTGDR2 281/4885SLC6A3 1327/4885SLC6A2 1537/4885 |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | CHRM2, ADRB1, ADRB2 | PTGDR2 256/4885SLC6A3 1391/4885SLC6A2 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.